Risk factors for community-acquired Escherichia coli bacteraemia: a systematic review protocol

Introduction: Rates of community-acquired Escherichia coli bacteraemia (ECB) have been consistently rising. As rates of antimicrobial resistance (AMR), particularly in Gram-negative bacteria, are also increasing, this is of concern both for management of individual patients and healthcare systems. There is currently little data on the risk factors for development of community-acquired ECB: this review aims to identify these risk factors in order to inform community interventions to reduce ECB as well as antibiotic prescribing policy. Methods and analysis: We will search Medline (Ovid), Embase (Ovid), Web of Science/Scopus and the Cochrane Central Register of Controlled Trials for published reports on observational and experimental primary research studies involving patients admitted to hospital with community-acquired ECB. Two reviewers will independently screen the studies for eligibility, perform data collection and assess study quality and risk of bias. Random effects meta-analyses will be performed if appropriate. Ethics and dissemination: No primary data will be collected for this study and so formal ethical approval is not required. We will publish the results of our review in relevant peer-reviewed medical journals, and will also seek to present them at relevant medical conferences. PROSPERO registration number: CRD42018104402

Download Full-text

Recurrence of cervical artery dissection: protocol for a systematic review

BMJ Open ◽

10.1136/bmjopen-2020-037124 ◽

2020 ◽

Vol 10 (9) ◽

pp. e037124

Author(s):

Elizabeth Lounsbury ◽

Brian Dewar ◽

Alexandra Davis ◽

Dean A Fergusson ◽

Dar Dowlatshahi ◽

...

Keyword(s):

Systematic Review ◽

Vertebral Artery Dissection ◽

Primary Data ◽

Artery Dissection ◽

Cervical Artery Dissection ◽

Cochrane Central Register ◽

Minor Trauma ◽

Central Register ◽

Cervical Artery ◽

Registration Number

IntroductionCervical artery dissection, including carotid and vertebral artery dissection, is an important cause of stroke in the young. Risk of developing cervical artery dissection has been associated with physical activity in various forms and has been presumed to be related to minor trauma and mechanical stretching of the cervical arteries. This systematic review will aim to synthesise data on the risk of recurrent cervical artery dissection after an initial dissection. This information may be applied to further understand the natural history of this disease, and potentially to help direct evidence-based discussions on safe return to activity after dissection.Methods and analysisA broad search of multiple electronic databases (Medline, Embase, Cochrane Central Register of Controlled Trials and Web of Science) will be conducted to identify studies published as of 13 November 2019, examining all-comers with cervical artery dissection observed over time. Studies will be screened by two independent reviewers in a two-level process to determine eligibility for inclusion. Data will be pooled from eligible articles and the main outcome of recurrent cervical artery dissection at 5 years will be determined using quantitative analysis.Ethics and disseminationEthics approval is not necessary as no primary data are being collected. The information will be disseminated in the form of a systematic review article which will be submitted to a peer-reviewed medical journal.PROSPERO registration numberCRD42020166105.

Download Full-text

Lopinavir/ritonavir for the treatment of COVID-19: A living systematic review protocol

10.1101/2020.04.11.20062109 ◽

2020 ◽

Cited By ~ 1

Author(s):

Francisca Verdugo-Paiva ◽

Ariel Izcovich ◽

Martín Ragusa ◽

Gabriel Rada

Keyword(s):

Systematic Review ◽

Direct Evidence ◽

Grey Literature ◽

Cochrane Central Register ◽

Randomised Trials ◽

Eligibility Criteria ◽

Web Based ◽

Central Register ◽

Review Protocol ◽

Meta Analyses

ABSTRACTObjectiveTo assess the efficacy and safety of lopinavir/ritonavir for the treatment of patients with COVID-19.DesignThis is the protocol of a living systematic review.Data sourcesWe will conduct searches in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature and in a centralised repository in L·OVE (Living OVerview of Evidence). L·OVE is a platform that maps PICO questions to evidence from Epistemonikos database. In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it covers and customised to group all COVID-19 evidence in one place. The search will cover the period until the day before submission to a journal.Eligibility criteria for selecting studies and methodsWe adapted an already published common protocol for multiple parallel systematic reviews to the specificities of this question.We will include randomised trials evaluating the effect of lopinavir/ritonavir— as monotherapy or in combination with other drugs — versus placebo or no treatment in patients with COVID-19. Randomised trials evaluating lopinavir/ritonavir in infections caused by other coronaviruses, such as MERS-CoV and SARS-CoV, and non-randomised studies in COVID-19 will be searched in case no direct evidence from randomised trials is found, or if the direct evidence provides low- or very low-certainty for critical outcomes.Two reviewers will independently screen each study for eligibility, extract data, and assess the risk of bias. We will perform random-effects meta-analyses and use GRADE to assess the certainty of the evidence for each outcome.A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit it if the conclusions change or there are substantial updates.Ethics and disseminationNo ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media.PROSPERO RegistrationSubmitted to PROSPERO (awaiting ID allocation).

Download Full-text

Sexual transmission of SARS-CoV-2 virus and its role in the spread of COVID-19: A living systematic review protocol

Medwave ◽

10.5867/medwave.2020.10.8062 ◽

2020 ◽

Vol 20 (10) ◽

pp. e8062-e8062

Author(s):

Giuliano Duarte ◽

Luis Ortiz-Muñoz ◽

María Belén Morales ◽

María Paz Acuña ◽

Gabriel Rada

Keyword(s):

Randomized Trials ◽

Direct Evidence ◽

Sexual Transmission ◽

Grey Literature ◽

Cochrane Central Register ◽

Eligibility Criteria ◽

Web Based ◽

Central Register ◽

Review Protocol ◽

Meta Analyses

Objective To provide a review of the literature on the presence of SARS-CoV-2 in the sexual fluids of patients with COVID-19 and to observe its possible sexual transmission in a timely, rigorous, and continuously updated manner. Data sources We will conduct searches in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature, and a centralized repository in L·OVE (Living OVerview of Evidence). L·OVE is a platform that maps PICO questions to evidence from the Epistemonikos database. In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it covers and customized to group all COVID-19 evidence in one place. The search will cover the period until the day before submission to a journal. Eligibility criteria for selecting studies and methods We adapted an already published standard protocol for multiple parallel systematic reviews to the specificities of this question. We will include randomized trials evaluating the sexual transmission of the SARS-CoV-2 virus. Randomized trials evaluating the sexual transmission of other coronaviruses, such as MERS-CoV and SARS-CoV, and non-randomized studies in COVID-19 will be searched if no direct evidence from randomized trials is found or if the direct evidence provides a low to a very low level of certainty for critical outcomes. Two reviewers will independently screen each study for eligibility, extract data, and assess the risk of bias. We will perform random-effects meta-analyses and use GRADE to assess the certainty of the evidence for each outcome. A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit the review if the conclusions change or if there are substantial updates. PROSPERO Registration (CRD42020189368).

Download Full-text

Natural history of recovery after intracerebral haemorrhage: a scoping review protocol

BMJ Open ◽

10.1136/bmjopen-2020-039460 ◽

2020 ◽

Vol 10 (8) ◽

pp. e039460

Author(s):

Sara Massicotte ◽

Ronda Lun ◽

Vignan Yogendrakumar ◽

Brian Dewar ◽

Alexandra Davies ◽

...

Keyword(s):

Ischaemic Stroke ◽

Scoping Review ◽

Intracerebral Haemorrhage ◽

Outcome Measurement ◽

Primary Data ◽

Cochrane Central Register ◽

Central Register ◽

History Of ◽

Study Population ◽

Review Protocol

IntroductionClinical trials for intracerebral haemorrhage typically measure outcomes in the same way and at the same time points as trials for ischaemic stroke. However, there is growing evidence that the trajectory of recovery following intracerebral haemorrhage may differ significantly from that following ischaemic stroke. A better understanding of current approaches to outcome assessment is essential to ensure that future trials examining treatments for intracerebral haemorrhage are designed appropriately.ObjectiveTo determine when and how outcomes are measured in patients with intracerebral haemorrhage.Methods and analysisWith the assistance of an information specialist, we will conduct a scoping review by searching MEDLINE, Embase, Cochrane Central Register of Controlled Trials and Web of Science for prospective studies of adults with primary intracerebral haemorrhage and documented outcomes with specified times. Two reviewers will independently collect data on included studies pertaining to publication data, study population information, timing of outcome and details of the outcome measurement tools used. The extracted data will be used to demonstrate the type and timing of outcome measures.Ethics and disseminationPrimary data will not be collected therefore formal ethics is not required. The findings of this study will be disseminated through peer-reviewed publications and through presentation at academic conferences.

Download Full-text

Macrolides for the treatment of COVID-19: A living systematic review protocol

10.31219/osf.io/rvp59 ◽

2020 ◽

Author(s):

Catalina Verdejo ◽

Laura Vergara-Merino ◽

Natalia Carvajal-Juliá ◽

Nicolás Meza ◽

Eva Madrid ◽

...

Keyword(s):

Systematic Review ◽

Direct Evidence ◽

Meta Analysis ◽

Grey Literature ◽

Cochrane Central Register ◽

Randomised Trials ◽

Web Based ◽

Central Register ◽

Registration Number ◽

Review Protocol

ObjectiveThis living systematic review aims to provide a timely, rigorous and continuously updated summary of the evidence available on the role of macrolides for the treatment of patients with COVID-19.Data sources We will conduct searches in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature and in a centralised repository in L·OVE (Living OVerview of Evidence). L·OVE is a platform that maps PICO questions to evidence from Epistemonikos database. In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it covers and customised to group all COVID-19 evidence in one place. The search will cover the period until the day before submission to a journal.Eligibility criteria for selecting studies and methods We adapted an already published common protocol for multiple parallel systematic reviews to the specificities of this question. We will include randomised trials evaluating the effect of macrolides — as monotherapy or in combination with other drugs — versus placebo or no treatment in patients with COVID-19. Randomised trials evaluating macrolides in infections caused by other coronaviruses, such as MERS-CoV and SARS-CoV, and non-randomised studies in COVID-19 will be searched in case we find no direct evidence from randomised trials, or if the direct evidence provides low- or very low-certainty for critical outcomes.Two reviewers will independently screen each study for eligibility, extract data, and assess the risk of bias. We will pool the results using meta-analysis and will apply the GRADE system to assess the certainty of the evidence for each outcome. A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit it every time the conclusions change or whenever there are substantial updates.Ethics and dissemination No ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media.PROSPERO Registration number CRD42020181032

Download Full-text

Mediators and theories of change in psychotherapy with adolescents: a systematic review protocol

BMJ Open ◽

10.1136/bmjopen-2020-042411 ◽

2021 ◽

Vol 11 (3) ◽

pp. e042411

Author(s):

Svenja Taubner ◽

Andrea Saliba ◽

Erkki Heinonen ◽

Sonja Protić ◽

Jana Volkert ◽

...

Keyword(s):

Systematic Review ◽

Mental Disorders ◽

Open Science ◽

Primary Data ◽

Data Set ◽

Ethical Approval ◽

Registration Number ◽

Theories Of Change ◽

Meta Analyses ◽

Prospective Longitudinal

IntroductionApproximately 75% of mental disorders emerge before the age of 25 years but less than half receive appropriate treatment. Little is known about the mechanisms underlying the therapeutic change of adolescents in psychotherapy. The ‘European Network of Individualised Psychotherapy Treatment of Young People with Mental Disorders’, funded by the European Cooperation in Science and Technology, will conduct the first systematic review to summarise the existing knowledge on mediators and theories of change in psychotherapy for adolescents.MethodA systematic review will be conducted, conforming to the reporting guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement recommendations. Electronic databases (PubMed and PsycINFO) have been systematically searched on 23 February 2020, for prospective, longitudinal and case-control designs which examine mediators of change. Participants will be adolescents between 10 and 19 years of age who suffer from a mental disorder or psychological difficulties and receive an intervention that aims at preventing, ameliorating and/or treating psychological problems.Ethics and disseminationEthical approval is not required for this systematic review as no primary data will be collected. The results will be published in a peer-reviewed journals and at conference presentations and will be shared with stakeholder groups. The whole data set will be offered to other research groups following recommendations of the open science initiative. Databases with the systematic search will be made openly available following open science initiatives.PROSPERO registration numberCRD42020177535.

Download Full-text

Infectious Diseases Data Observatory (IDDO) Visceral Leishmaniasis Library of Clinical Therapeutic Studies: A Protocol for a Living Systematic Review of Clinical Studies

10.21203/rs.3.rs-1159661/v1 ◽

2021 ◽

Author(s):

sauman Singh-Phulgenda ◽

Sumayyah Rashan ◽

Eli Harriss ◽

Prabin Dahal ◽

Caitlin Naylor ◽

...

Keyword(s):

Systematic Review ◽

Visceral Leishmaniasis ◽

Drug Efficacy ◽

Cochrane Central Register ◽

Central Register ◽

Medical Librarian ◽

Registration Number ◽

Study Characteristics ◽

Vector Borne ◽

Meta Analyses

Abstract Introduction: Visceral Leishmaniasis (VL) is a vector-borne disease caused by protozoan parasites of the genus Leishmania. The disease is endemic in parts of South Asia, East Africa, South America and the Mediterranean region, with an estimated 50,000 to 90,000 cases occurring annually. A living systematic review of existing scientific literature is proposed to identify clinical drug efficacy studies against VL, conducted following the Preferred Reporting Items for Systematic-Reviews and Meta-Analyses (PRISMA) guidelines. Methods and analysis: The proposed living systematic review builds on a previous systematic review first carried out in 2016, and the current protocol is designed to capture any published or registered VL clinical study from Nov-2021 onwards. The following databases will be searched by a medical librarian: PubMed, Ovid Embase, Scopus, Web of Science Core Collection, Cochrane Central Register of Controlled Trials, clinicaltrials.gov, WHO ICTRP, as well as IMEMR, IMSEAR, and LILACS from the WHO Global Index Medicus. The systematic review will consider both randomised and non-randomised interventional studies, including single-armed studies. Ethics and dissemination: A database of eligible studies, including study characteristics, is openly available (https://www.iddo.org/tool/vl-surveyor) and will be continually updated every six months. All findings will be published in a peer reviewed journal.PROSPERO registration number: CRD42021284622

Download Full-text

Prognostic factors for severity and mortality in patients infected with COVID-19: A living systematic review protocol

10.1101/2020.04.08.20056598 ◽

2020 ◽

Author(s):

Ariel Izcovich ◽

Martín Ragusa ◽

Verónica Sanguine ◽

Fernando Tortosa ◽

Federico Espinosa ◽

...

Keyword(s):

Systematic Review ◽

Prognostic Factors ◽

Grey Literature ◽

Cochrane Central Register ◽

Traditional Media ◽

Eligibility Criteria ◽

Web Based ◽

Central Register ◽

Review Protocol ◽

Meta Analyses

ABSTRACTObjectiveThe objective of our systematic review is to identify prognostic factors that can potentially be used in decision-making related to the care of patients infected with COVID-19.DesignThis is the protocol of a living systematic review.Data sourcesWe will conduct searches in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature and in a centralised repository in L·OVE (Living OVerview of Evidence). L·OVE is a platform that maps PICO questions to evidence from Epistemonikos database. In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence covered and customised to group all COVID-19 evidence in one place. The search will continue until the day before submission to a journal.Eligibility criteria for selecting studies and methodsWe will follow a common protocol for multiple parallel systematic reviews, already published and submitted to PROSPERO (awaiting ID allocation).We will include studies that assess patients with confirmed or suspected SARS-CoV-2 infection and inform the relation between potential prognostic factors and death or disease severity. Two groups of two reviewers will independently screen studies for eligibility, extract data and assess the risk of bias. We will perform meta-analyses and use GRADE to assess the certainty of evidence for each prognostic factor and outcome.A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit it if the conclusions change or there are substantial updates.Ethics and disseminationNo ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media.PROSPERO RegistrationSubmitted to PROSPERO (awaiting ID allocation).

Download Full-text

Sexual transmission of SARS-CoV-2 virus and its role in the spread of COVID-19: A living systematic review protocol

10.31219/osf.io/t3vq9 ◽

2020 ◽

Author(s):

Giuliano Duarte Anselmi ◽

Luis E. Ortiz-Muñoz ◽

María Belén Morales Ferrer ◽

María Paz Acuña ◽

Gabriel Rada

Keyword(s):

Randomized Trials ◽

Direct Evidence ◽

Sexual Transmission ◽

Grey Literature ◽

Cochrane Central Register ◽

Randomised Trials ◽

Web Based ◽

Central Register ◽

Review Protocol ◽

Meta Analyses

ObjectiveTo evaluate the presence and duration of SARS-CoV-2 in genital fluids, and determine the risk of sexual transmission of the SARS-CoV-2 virus.DesignThis is the protocol of a living systematic review.Data sources We will conduct searches in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature and in a centralised repository in L·OVE (Living OVerview of Evidence). L·OVE is a platform that maps PICO questions to evidence from Epistemonikos database. In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it covers and customised to group all COVID-19 evidence in one place. The search will cover the period until the day before submission to a journal.Eligibility criteria for selecting studies and methods We adapted an already published common protocol for multiple parallel systematic reviews to the specificities of this question. We will include randomized trials evaluating the sexual transmission of SARS-CoV-2 virus. Randomised trials evaluating the sexual transmission of other coronaviruses, such as MERS-CoV and SARS-CoV, and non-randomised studies in COVID-19 will be searched in case no direct evidence from randomised trials is found, or if the direct evidence provides low- or very low-certainty for critical outcomes.Two reviewers will independently screen each study for eligibility, extract data, and assess the risk of bias. We will perform random-effects meta-analyses and use GRADE to assess the certainty of the evidence for each outcome. A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit it if the conclusions change or there are substantial updates.Ethics and dissemination No ethics approval is considered necessary. The results of this review will be widely disseminated via peer-reviewed publications, social networks and traditional media.PROSPERO Registration Submitted to PROSPERO (CRD42020189368).

Download Full-text

Efficacy and safety of aliskiren combination therapy: a protocol for an umbrella review

BMJ Open ◽

10.1136/bmjopen-2020-043807 ◽

2021 ◽

Vol 11 (3) ◽

pp. e043807

Author(s):

Jiantong Shen ◽

Wenming Feng ◽

Yike Wang ◽

Qiyuan Zhao ◽

Billong Laura Flavorta ◽

...

Keyword(s):

Combination Therapy ◽

Systematic Reviews ◽

Cochrane Library ◽

Umbrella Review ◽

Quality Of Reporting ◽

Ethical Approval ◽

Registration Number ◽

Third Person ◽

Meta Analyses ◽

The Impact

IntroductionEfficacy of aliskiren combination therapy with other antihypertensive has been evaluated in the treatment of patients with hypertension in recent systematic reviews. However, most previous reviews only focused on one single health outcome or one setting, none of them made a full summary that assessed the impact of aliskiren combination treatment comprehensively. As such, this umbrella review based on systematic reviews and meta-analyses is aimed to synthesise the evidences on efficacy, safety and tolerability of aliskiren-based therapy for hypertension and related comorbid patients.Methods and analysisA comprehensive search of PubMed, EMBASE, Cochrane Library, CNKI published from inception to August 2020 will be conducted. The selected articles are systematic reviews which evaluated efficacy, safety and tolerability of aliskiren combination therapy. Two reviewers will screen eligible articles, extract data and evaluate quality independently. Any disputes will be resolved by discussion or the arbitration of a third person. The quality of reporting evidence will be assessed using the Assessment of Multiple Systematic Reviews V.2 tool tool. We will take a mixed-methods approach to synthesising the review literatures, reporting summary of findings tables and iteratively mapping the results.Ethics and disseminationEthical approval is not required for the study, as we would only collect data from available published materials. This umbrella review will be also submitted to a peer-reviewed journal for publication after completion.PROSPERO registration numberCRD42020192131.

Download Full-text